骨肉瘤P-糖蛋白、胎盘型谷胱甘肽-S-转移酶和DNA拓朴酶Ⅱ的表达及其与预后的关系
作者：牟江洪 王东 陈俐
单位：第三军医大学大坪医院野战外科研究所病理科 重庆 400042
关键词：骨肉瘤；多药耐药性；预后
诊断病理学杂志000111摘 要：目的 探讨骨肉瘤组织中P-糖蛋白(P-gp)、胎盘型谷胱甘肽-S-转移酶(GST-π)和DNA拓朴酶Ⅱ(TopoⅡ)的表达及其与预后的关系。方法 应用SP法检测P-gp、GST-π、TopoⅡ在80例骨肉瘤中的表达，并应用COX比例风险模型评估它们对预后的影响。结果 80例骨肉瘤中P-gp、GST-π和TopoⅡ的表达率分别为36.25%、91.25%和47.5%，其中P-gp和TopoⅡ表达与WHO新分型和预后显著相关(P<0.05)。结论 P-gp、GST-π、和ToPo Ⅱ等多因素联合作用是骨肉瘤多药耐药性(multi-drug resistance,MDR)的主要作用机制，并且P-gp和TopoⅡ可能成为评估骨肉瘤预后的有价值的指标。
, http://www.100md.com
分类号：R737.9 文献标识码：A
文章编号：1007-8096(2000)01-0030-03
Expression of P-gp, GST-π and Topoa Ⅱ nnd its prognostic significance in osteosarcoma
Mou Jianhong ,Wang Dong ,Chen Li
(Department of Pathology, Daping Hospital and Research Institute of Surgery,Third Military Medical University,Chonsping,400042)
Abstract：Objective To study the expression of P-glycoprotein (P-gp), Glutathione-S-transferases π (GST-π) and DNA topoisomerase Ⅱ (Topo Ⅱ ) in osteosarcoma, and their correlation with prognosis. Method Expression of P-gp,GST-π and Topo Ⅱ were detected in 80 cases of osteosarcomas by SP immunohistochemical staining,and the correlalion with prognosis was analyzed by a COX proportion hazard model. Results The positive rates of P-gp, GST-πand Topo Ⅱ were 36.25% ,91.25% and 47.5% respectively in 80 cases of osteosarcomas.A significant relationship was found between P-gp and Topo Ⅱ expression and WHO classification, as well as the prognosis of the patients. Conclusions Co-expression of P-gp, GST-πand Topo Ⅱ may be the chief mechanism of multi-drug resistance and an inportant panameter to predict the prognosis of patients with osteosatcoma.
, 百拇医药
Keywords：ossteosarcoma MDR prognosis
参考文献：
[1]Bradley G, Juranka PF, Ling V. Mechanisms of multidrug resistance.Biochim Biophys,1988,948:87-128
[2]Gottesman MM, Pastan Ⅰ.Biochemistry of multidrug resistance mediated by the multidrug transporter.Annu Rev Biochem,1993,63:385-427
[3]Coles B,Ketterer B.The role of glutathione and glutathione transferases in chegnical carcinogenesis. Crit. Rev. Biochem. Mol,Biol,1990,25:47
, http://www.100md.com
[4]Scgbeuder E,Hsiang YH, Liu LF.DAN topoisomerase asanticancer drug targets.Adv Pharmacol,1990,21:149-83
[5]Baldini N, Scotlandi K,Manara MC,et al.Expression of Pglytoprotein in high-grade osteosarcomas in relation to clinical outcome.N. Engl. J. Med,1995,333:1380-1385
[6]Schajowicz F, Sissons HA, Sobin H.The World Health Organizatuib's his-tologic classification of bone tumor.A commentary on the second edition.Cancer, 1995,75:1208-1218
, 百拇医药
[7]李羲,郭先健,王东,等.P-糖蛋白在正常胎儿组织中的表过,第三军医大学学后,1995, 17:473
[8]Toffoli G, Viel A, Tumiotto L, et al. Expression of glutathione-S-trans-ferase-π in human tumors.Eur.J.Cancer,1992,28A:1441
[9]Iino K,Sasano H,Yabuki N,et al. DNA topoisomerase Ⅱ alpha and Ki-67 in human adrenocortical neoplasms:a possible marker of differentiation between adenomas and carcinomas. Mod Pathol,1997,10:9901-7
[10]Fogt F,Nikulasson ST,Holden JA,et al.Topoisomerase Ⅱ alpha expres-sion in normal inflammatory and neoplastic conditions of the gastric and colonic mucosa.Mod Pathol,1997,10:4296-302
收稿日期：1999-07-15
修稿日期：1999-09-27, 百拇医药
单位：第三军医大学大坪医院野战外科研究所病理科 重庆 400042
关键词：骨肉瘤；多药耐药性；预后
诊断病理学杂志000111摘 要：目的 探讨骨肉瘤组织中P-糖蛋白(P-gp)、胎盘型谷胱甘肽-S-转移酶(GST-π)和DNA拓朴酶Ⅱ(TopoⅡ)的表达及其与预后的关系。方法 应用SP法检测P-gp、GST-π、TopoⅡ在80例骨肉瘤中的表达，并应用COX比例风险模型评估它们对预后的影响。结果 80例骨肉瘤中P-gp、GST-π和TopoⅡ的表达率分别为36.25%、91.25%和47.5%，其中P-gp和TopoⅡ表达与WHO新分型和预后显著相关(P<0.05)。结论 P-gp、GST-π、和ToPo Ⅱ等多因素联合作用是骨肉瘤多药耐药性(multi-drug resistance,MDR)的主要作用机制，并且P-gp和TopoⅡ可能成为评估骨肉瘤预后的有价值的指标。
, http://www.100md.com
分类号：R737.9 文献标识码：A
文章编号：1007-8096(2000)01-0030-03
Expression of P-gp, GST-π and Topoa Ⅱ nnd its prognostic significance in osteosarcoma
Mou Jianhong ,Wang Dong ,Chen Li
(Department of Pathology, Daping Hospital and Research Institute of Surgery,Third Military Medical University,Chonsping,400042)
Abstract：Objective To study the expression of P-glycoprotein (P-gp), Glutathione-S-transferases π (GST-π) and DNA topoisomerase Ⅱ (Topo Ⅱ ) in osteosarcoma, and their correlation with prognosis. Method Expression of P-gp,GST-π and Topo Ⅱ were detected in 80 cases of osteosarcomas by SP immunohistochemical staining,and the correlalion with prognosis was analyzed by a COX proportion hazard model. Results The positive rates of P-gp, GST-πand Topo Ⅱ were 36.25% ,91.25% and 47.5% respectively in 80 cases of osteosarcomas.A significant relationship was found between P-gp and Topo Ⅱ expression and WHO classification, as well as the prognosis of the patients. Conclusions Co-expression of P-gp, GST-πand Topo Ⅱ may be the chief mechanism of multi-drug resistance and an inportant panameter to predict the prognosis of patients with osteosatcoma.
, 百拇医药
Keywords：ossteosarcoma MDR prognosis
参考文献：
[1]Bradley G, Juranka PF, Ling V. Mechanisms of multidrug resistance.Biochim Biophys,1988,948:87-128
[2]Gottesman MM, Pastan Ⅰ.Biochemistry of multidrug resistance mediated by the multidrug transporter.Annu Rev Biochem,1993,63:385-427
[3]Coles B,Ketterer B.The role of glutathione and glutathione transferases in chegnical carcinogenesis. Crit. Rev. Biochem. Mol,Biol,1990,25:47
, http://www.100md.com
[4]Scgbeuder E,Hsiang YH, Liu LF.DAN topoisomerase asanticancer drug targets.Adv Pharmacol,1990,21:149-83
[5]Baldini N, Scotlandi K,Manara MC,et al.Expression of Pglytoprotein in high-grade osteosarcomas in relation to clinical outcome.N. Engl. J. Med,1995,333:1380-1385
[6]Schajowicz F, Sissons HA, Sobin H.The World Health Organizatuib's his-tologic classification of bone tumor.A commentary on the second edition.Cancer, 1995,75:1208-1218
, 百拇医药
[7]李羲,郭先健,王东,等.P-糖蛋白在正常胎儿组织中的表过,第三军医大学学后,1995, 17:473
[8]Toffoli G, Viel A, Tumiotto L, et al. Expression of glutathione-S-trans-ferase-π in human tumors.Eur.J.Cancer,1992,28A:1441
[9]Iino K,Sasano H,Yabuki N,et al. DNA topoisomerase Ⅱ alpha and Ki-67 in human adrenocortical neoplasms:a possible marker of differentiation between adenomas and carcinomas. Mod Pathol,1997,10:9901-7
[10]Fogt F,Nikulasson ST,Holden JA,et al.Topoisomerase Ⅱ alpha expres-sion in normal inflammatory and neoplastic conditions of the gastric and colonic mucosa.Mod Pathol,1997,10:4296-302
收稿日期：1999-07-15
修稿日期：1999-09-27, 百拇医药